Ex-GSK chief An­drew Wit­ty sum­moned back to the front­lines of vac­cine de­vel­op­ment at em­bat­tled WHO

Dur­ing his 10-year tenure at Glax­o­SmithK­line, An­drew Wit­ty made vac­cines one of his sig­na­ture ar­eas of fo­cus, lead­ing the phar­ma gi­ant to an ap­proval for an in­fluen­za vac­cine dur­ing the H1N1 pan­dem­ic and bag­ging No­var­tis’ vac­cine unit in an as­set swap be­fore he re­tired in 2017.

Now, two years in­to his new ca­reer man­ag­ing drug ben­e­fits, Wit­ty is back in the front­lines of the race against a dead­ly virus in­fil­trat­ing the world.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER